Search

Author/Creator De Castro Carpeno, J.

1. 2MO First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in metastatic non-small cell lung cancer (mNSCLC): Clinical outcomes and biomarker analyses from CheckMate 592. (December 2022)

Authors:
Gettinger, S.; Schenker, M.; De Langen, J.; Fischer, J.R.; Morgensztern, D.; Ciuleanu, T-E.; Beck, T.; De Castro Carpeno, J.; Schumann, C.; Yang, X.; Telivala, B.; Deschepper, K.; Nadal, E.; Schalper, K.; Spires, T.; Balli, D.; Nassar, A.; Karam, S.; Bhingare, A.; Spigel, D.R.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC. (January 2020)

Authors:
Lind, M.; Gettinger, S.; Borghaei, H.; Brahmer, J.; Chow, L.; Burgio, M.; De Castro Carpeno, J.; Pluzanski, A.; Arrieta, O.; Frontera, O. Aren; Chiari, R.; Butts, C.; Wojcik-Tomaszewska, J.; Coudert, B.; Garassino, M.; Ready, N.; Felip, E.; Garcia, M. Alonso; Waterhouse, D.; Domine, M.
Journal:
Lung cancer
Issue:
Volume 139(2020)Supplement 1
Page Start:
S49
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search